

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> SIGMA HEALTHCARE LIMITED ('Sigma')
<b>ABN</b> 15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Vikesh RAMSUNDER
<b>Date of last notice</b>	15 June 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	13 June 2023
<b>No. of securities held prior to change</b>	1) 2,964,845 rights to acquire fully paid ordinary shares pursuant to the terms of the Sigma Rights Plan ( <b>Rights</b> ). 2) 10,179,605 fully paid ordinary shares acquired with a limited recourse loan provided by Sigma pursuant to the terms of the Sigma Loan Funded Share Plan ( <b>LFSP Shares</b> ). 3) 240,462 rights to acquire fully paid ordinary shares pursuant to the terms of Sigma's 2022 / 2023 Short Term Incentive Plan ( <b>2022 / 2023 STI Rights</b> ).
<b>Class</b>	Rights to acquire fully paid ordinary shares pursuant to the terms of Sigma's 2023 Executive Equity Grant Plan ( <b>EEG Rights</b> ).

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	3,112,283 EEG Rights as approved by shareholders at Sigma's Annual General Meeting held on 17 May 2023.
<b>Number disposed</b>	Nil.
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	EEG Rights are issued for nil consideration. On vesting, one EEG Right is converted into one fully paid ordinary share in Sigma. The EEG Rights represent part of the employee incentive scheme component of remuneration for Vikesh Ramsunder. Vesting and other conditions relating to the EEG Rights are set out in Sigma's 2023 Notice of Annual General Meeting.
<b>No. of securities held after change</b>	Direct interest in 2,964,845 Rights, 10,179,605 LFSP Shares, 240,462 2022 / 2023 STI Rights and 3,112,283 EEG Rights.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of EEG Rights in accordance with the 2023 Executive Equity Grant Plan.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A